NVDA
SLP
New sidekick, same drug-development grind
Simulations Plus just announced a technical collaboration with Nvidia, and the goal is very 2026: make drug modeling faster, smarter, and less of a computational traffic jam. The companies are pairing GPU-accelerated simulation with AI-assisted workflows for quantitative systems pharmacology and pharmacokinetics/pharmacodynamics work.
Why anyone in the market should care
If this works the way management hopes, simulations could run up to 75% faster. That matters because in drug development, time is money — and so is the ability to test more hypotheses without having to trim the model down first like you’re deleting apps to free up your phone storage.
The pharma pitch
The companies say they’ll also bring select pharmaceutical partners into the mix to test the tools in real-world workflows, with an early focus on complex modeling cases. That’s the important part for investors: this isn’t just a shiny demo, it’s an attempt to turn AI hype into something customers might actually pay for.
Big picture
For Simulations Plus, this is less about a headline grab and more about credibility. Nvidia brings the AI halo and the horsepower; SLP brings the drug-modeling niche. If the collaboration translates into faster workflows and stickier pharma adoption, that’s the kind of partnership that can quietly become a real growth lever.